Evidence mapPaperPMID 31421395Full record

Trial reportNutrition research (New York, N.Y.)2019

Daidzein and genistein have differential effects in decreasing whole body bone mineral density but had no effect on hip and spine density in premenopausal women: A 2-year randomized, double-blind, placebo-controlled study.

Fatima Nayeem, Nai-Wei Chen, Manubai Nagamani, Karl E Anderson, Lee-Jane W Lu

Open access · greenAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Nutrition research (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Targeting Breast Cancer Stem Cells Using Naturally Occurring Phytoestrogens.International journal of molecular sciences · 2022
    Review
  8. Review
  9. Review
  10. Therapeutic Potential of Isoflavones with an Emphasis on Daidzein.Oxidative medicine and cellular longevity · 2021
    Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Fatima NayeemDepartment of Preventive Medicine and Community Health The University of Texas Medical Branch, Galveston, TX 77555. Electronic address: fanayeem@utmb.edu.
Nai-Wei ChenDepartment of Preventive Medicine and Community Health The University of Texas Medical Branch, Galveston, TX 77555. Electronic address: Nai-Wei.Chen@beaumont.org.
Manubai NagamaniDepartment of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, TX 77555. Electronic address: mnagaman@gmail.com.
Karl E AndersonDepartment of Preventive Medicine and Community Health The University of Texas Medical Branch, Galveston, TX 77555. Electronic address: kanderso@utmb.edu.
Lee-Jane W LuDepartment of Preventive Medicine and Community Health The University of Texas Medical Branch, Galveston, TX 77555. Electronic address: llu@utmb.edu.
The University of Texas Medical Branch at Galveston · US

Funding

Service Core 4: Cell BiologyP30ES006676 · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · 1995 to 2005
$8.7M
Mammographic Density and Soy IsoflavonesR01CA095545 · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · 2003 to 2005
$1.6M
NCATS NIH HHS UL1 TR000071NCI NIH HHS R01 CA095545NIEHS NIH HHS P30 ES006676
6 · The paper itself

Abstract

Soy isoflavones are potentially beneficial phytoestrogens, but their tissue-selective effects in women are poorly understood. We tested the hypothesis that soy isoflavones affect bone mineral density (BMD), which may be influenced by individual differences in isoflavone metabolism and serum calcium levels. Ninety-nine healthy premenopausal women were randomized to isoflavones (136.6 mg aglycone equivalence) and 98 to placebo for 5 days per week for up to 2 years. BMD, serum calcium, and urinary excretion of daidzein and genistein were measured before and during treatment. In 129 adherent subjects, we found that isoflavone exposure, determined by urinary excretion levels, but not by dose assignment, interacted with serum calcium in affecting whole body BMD, but not hip and spine BMD. The regression coefficient was -0.042 for genistein excretion (GE) and 0.091 for the interaction between GE and serum calcium (all P < .05). Daidzein excretion had similar but marginal effect. Genistein significantly decreased whole body BMD only at low normal serum calcium levels but increased whole body BMD at higher serum calcium levels. Comparing maximum to minimum GE, mean changes in whole body BMD were +0.033 and -0.113 g/cm

Indexed as

Lumbar VertebraePelvic BonesPremenopauseAbsorptiometry, PhotonAdultBone DensityCalciumDouble-Blind MethodFemaleGenisteinHumansIsoflavonesPhytoestrogensPlacebosCalciumdaidzeinGenisteinIsoflavonesPhytoestrogensPlacebosBone metabolismCalcium homeostasisDaidzeinGenisteinHormone receptor modulatorsIsoflavones

Identifiers

PMID31421395
PMCPMC6823144
OpenAlexW2954459998

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.